Evidence map›Paper›PMID 34788349›Full record

ArticlePloS one2021

Breadth of CD8 T-cell mediated inhibition of replication of diverse HIV-1 transmitted-founder isolates correlates with the breadth of recognition within a comprehensive HIV-1 Gag, Nef, Env and Pol potential T-cell epitope (PTE) peptide set.

Peter Hayes, Natalia Fernandez, Christina Ochsenbauer, Jama Dalel, Jonathan Hare, Deborah King, Lucas Black, Claire Streatfield, Vanaja Kakarla, Gladys Macharia and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. HIV T-cell immunogen design and delivery.Current opinion in HIV and AIDS · 2022
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Peter HayesIAVI Human Immunology Laboratory, Imperial College, London, United Kingdom.ORCID 0000-0002-1251-934X
Natalia FernandezIAVI Human Immunology Laboratory, Imperial College, London, United Kingdom.
Christina OchsenbauerUniversity of Alabama, Birmingham, Alabama, United States of America.ORCID 0000-0003-1166-5879
Jama DalelIAVI Human Immunology Laboratory, Imperial College, London, United Kingdom.
Jonathan HareIAVI Human Immunology Laboratory, Imperial College, London, United Kingdom.
Deborah KingIAVI Human Immunology Laboratory, Imperial College, London, United Kingdom.
Lucas BlackIAVI Human Immunology Laboratory, Imperial College, London, United Kingdom.ORCID 0000-0002-4463-6911
Claire StreatfieldIAVI Human Immunology Laboratory, Imperial College, London, United Kingdom.
Vanaja KakarlaIAVI Human Immunology Laboratory, Imperial College, London, United Kingdom.
Gladys MachariaIAVI Human Immunology Laboratory, Imperial College, London, United Kingdom.ORCID 0000-0002-5605-5604
Julia MakindeIAVI Human Immunology Laboratory, Imperial College, London, United Kingdom.
Matt PriceIAVI, New York, New York, United States of America.
Eric HunterEmory Vaccine Center, Atlanta, Georgia, United States of America.
IAVI protocol C investigators
Jill GilmourIAVI Human Immunology Laboratory, Imperial College, London, United Kingdom.
Imperial College London · GBEmory and Henry College · USInternational AIDS Vaccine Initiative · USUniversity of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Full characterisation of functional HIV-1-specific T-cell responses, including identification of recognised epitopes linked with functional antiviral responses, would aid development of effective vaccines but is hampered by HIV-1 sequence diversity. Typical approaches to identify T-cell epitopes utilising extensive peptide sets require subjects' cell numbers that exceed feasible sample volumes. To address this, CD8 T-cells were polyclonally expanded from PBMC from 13 anti-retroviral naïve subjects living with HIV using CD3/CD4 bi-specific antibody. Assessment of recognition of individual peptides within a set of 1408 HIV-1 Gag, Nef, Pol and Env potential T-cell epitope peptides was achieved by sequential IFNγ ELISpot assays using peptides pooled in 3-D matrices followed by confirmation with single peptides. A Renilla reniformis luciferase viral inhibition assay assessed CD8 T-cell-mediated inhibition of replication of a cross-clade panel of 10 HIV-1 isolates, including 9 transmitted-founder isolates. Polyclonal expansion from one frozen PBMC vial provided sufficient CD8 T-cells for both ELISpot steps in 12 of 13 subjects. A median of 33 peptides in 16 epitope regions were recognised including peptides located in previously characterised HIV-1 epitope-rich regions. There was no significant difference between ELISpot magnitudes for in vitro expanded CD8 T-cells and CD8 T-cells directly isolated from PBMCs. CD8 T-cells from all subjects inhibited a median of 7 HIV-1 isolates (range 4 to 10). The breadth of CD8 T-cell mediated HIV-1 inhibition was significantly positively correlated with CD8 T-cell breadth of peptide recognition. Polyclonal CD8 T-cell expansion allowed identification of HIV-1 isolates inhibited and peptides recognised within a large peptide set spanning the major HIV-1 proteins. This approach overcomes limitations associated with obtaining sufficient cell numbers to fully characterise HIV-1-specific CD8 T-cell responses by different functional readouts within the context of extreme HIV-1 diversity. Such an approach will have useful applications in clinical development for HIV-1 and other diseases.

Indexed as

CD8-Positive T-LymphocytesEpitopes, T-LymphocyteHIV-1HIV InfectionsVirus ReplicationAdultFemalegag Gene Products, Human Immunodeficiency VirusHumansMalenef Gene Products, Human Immunodeficiency VirusPeptidesEpitopes, T-Lymphocytegag Gene Products, Human Immunodeficiency Virusnef Gene Products, Human Immunodeficiency VirusPeptides

Identifiers

PMID34788349
PMCPMC8598018
OpenAlexW3213677581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.